Response to Comment on Russell et al. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care 2023;46:1005

Response to Comment on Russell et al. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care 2023;46:1005–1013

Published:2023-10-27 Issue:11 Volume:46 Page:e210-e211
ISSN:0149-5992
Container-title:Diabetes Care
language:en
Short-container-title:

Author:

Russell William E.¹^ORCID,Moore Daniel J.²^ORCID,Herold Kevan C.³^ORCID

Affiliation:

1. 1Departments of Pediatrics and Cell & Developmental Biology, Vanderbilt University Medical Center, Nashville, TN

2. 2Departments of Pediatrics and Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN

3. 3Yale University, New Haven, CT

Funder

the Eunice Kennedy Shriver National Institute of Child Health and Human Development

National Institute of Allergy and Infectious Diseases

National Institutes of Health (NIH) through the National Institute of Diabetes and Digestive and Kidney Diseases

Publisher

American Diabetes Association

Subject

Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://diabetesjournals.org/care/article-pdf/46/11/e210/737088/dci230050.pdf

Reference6 articles.

1. Comment on Russell et al. Abatacept for delay of type 1 diabetes progression in stage 1 relatives at risk: a randomized, double-masked, controlled trial. Diabetes Care 2023;46:1005–1013 (Letter);Pinheiro;Diabetes Care,2023

2. Cyclosporin increases the rate and length of readmissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial;Feutren;Lancet,1986

3. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus;Silverstein;N Engl J Med,1988

4. Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial;Gitelman;Lancet Diabetes Endocrinol,2021

5. Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial;von Herrath;Lancet Diabetes Endocrinol,2021